Genomic Health Inc.
Latest From Genomic Health Inc.
The UK's National Institute for Health and Care Excellence (NICE) has included Myriad Genetics' EndoPredict in its recommendations for guiding adjuvant chemotherapy decisions for certain early breast cancer patients. The recommendation comes just a few weeks after new data showing the long-term prognostic value of the EndoPredict test was presented at the San Antonio Breast Cancer Symposium. The company is also making progress on its Vectra rheumatoid arthritis prognostic system with the publication of a large commercial cohort and several clinical studies on development of the adjusted Vectra score.
The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.
The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in September and October 2017.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Genomic Health Inc.
- Senior Management
Kimberly J Popovits, Chmn., Pres & CEO
G. Bradley Cole, CFO & COO
Steven Shak, MD, CSO
Frederic Pla, PhD, Chief Bus. & Prod. Dev. Officer
- Contact Info
Genomic Health Inc.
Phone: (650) 556-9300
101 Galveston Dr.
Redwood City, CA 94063
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.